Multiple Sclerosis (MS) News, Research Studies | MS Research Articles

Multiple Sclerosis


Featured Article

Latest News

FDA to Review Data on Shorter Infusion Time for Ocrelizumab

The FDA has accepted for review the supplemental Biologics License Application (sBLA) for a 2-hour Ocrevus (ocrelizumab; Genentech) infusion time, shortening the conventional infusion duration for patients with relapsing or primary progressive multiple sclerosis (MS).
Next post in Multiple Sclerosis